49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
- Resource Type
- Abstract
- Authors
- Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R.
- Source
- In Journal of Thoracic Oncology April 2023 18(4) Supplement:S70-S71
- Subject
- Language
- ISSN
- 1556-0864